Panhematin powder for solution: Sterility concern
Brand(s)
Last updated
Summary
Product
Panhematin 268 mg/vial powder for solution
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Audience
Healthcare
Hospitals
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot numbers |
|---|---|---|---|---|---|
Recordati Rare Diseases Canada |
Panhematin powder for solution |
DIN 02478765 |
Powder for Solution |
Hemin 268 mg/vial |
485407C |
Issue
Product sterility may be compromised in affected lot.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Wholesalers, Retailers, Healthcare Establishments
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Biologic or vaccine
Companies
Recalling firm:
Recordati Rare Diseases Canada (care of McKesson Specialized Distribution)
8449 Lawson Rd, Unit 102
Milton, Ontario L9T 9L1 Canada
Market authorization holder:
Recordati Rare Diseases Canada Inc.
3080 Yonge Street, Suite 6060
Toronto, Ontario, M4N 3N1 Canada
Published by
Health Canada
Audience
Healthcare
Hospitals
Recall class
Type I
Identification number
RA-76042
Get notified
Receive notifications for new and updated recalls and alerts by category.